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Pragmatism in clinical trials arose from concerns that many trials did not adequately inform practice 
because they were optimized to determine efficacy [1]. Since such trials were performed in relatively 
small sample sizes in expert sites with highly selected participants they could be overestimating 
benefits and underestimating harm. This led to the belief that more pragmatic trials were required, 
designed to show the intervention real world effectiveness in broad patient groups. Medical 
researchers, academic and commercial, must deliver healthcare innovations (drugs, devices or other 
interventions) that are safe, beneficial, and identify subgroups with greatest benefit relative to risk 
and are cost-effective. A broad view of an intervention, including approaches to improve its 
effectiveness, is critical. An ideal trial includes a population relevant for the intervention, a control 
group treated with an acceptable standard of care, outcomes that are meaningful, and conducted 
and analyzed to a high quality. Pragmatic trials frequently include complex interventions, sometimes 
consisting of several interacting components [2], often involving the skills and experience of one or 
more healthcare professionals to deliver the intervention – for example surgery, physiotherapy or 
cognitive behavioural therapy.    
 
This article does not provide a definitive exposition of methodology for pragmatic studies, but rather 
we explore the contexts where a pragmatic design is most and least attractive, identifying the 
strengths and limitations of, and challenges in implementing, pragmatic trials. 
 
What is a Pragmatic Trial? 
Schwartz and Lellouch [1] proposed a distinction between explanatory trials confirming a 
physiological or clinical hypothesis and pragmatic trials informing a clinical or policy decision by 
providing evidence for the intervention’s adoption into real world clinical practice. The original 
PRECIS tool [3] attempted to clarify the concept of Pragmatism and provided a guide, scoring system 
and graphical representation of a trial’s pragmatic features. Features covered i) recruitment of 
investigators and participants, ii) the intervention and its delivery, iii) study follow-up and iv) study 
outcomes, their determination and analysis. Many trials could be deemed pragmatic on at least one 
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of these dimensions, but few are truly pragmatic on all.  Pragmatism has been discussed widely [4-
20], and a special issue of Clinical Trials had twelve articles focused on ethical and regulatory issues 
in pragmatic trials [e.g. 21]. The requirements for pragmatism were loosened significantly in PRECIS-
2 [22] and a pragmatic extension to the CONSORT statement has been proposed [23]. Key 
dimensions for assessing the degree of trial pragmatism, following PRECIS-2, are given in Table 1. 
Trials used as pragmatic exemplars throughout this article are summarized in Table 2. 
 
What are the greatest challenges to Pragmatism and potential solutions?   
 
Recruitment of study participants (Dimensions 1, 2: Table 1) 
Pragmatic trials require that trial participants are similar to those who would receive the 
intervention if it became usual care, which may be unknown for novel interventions. Participation in 
trials has fallen over time; for example, in individuals without established disease a less than 10% 
response to a screening invitation is common. The healthy volunteer effect and competing 
recruitment from other studies, particularly in academic centers, undermine attempts to achieve 
generalizability. Financial incentives associated with recruitment to industry studies can significantly 
impact recruitment to less well funded academic trials. Minimization of inclusion/exclusion criteria 
and reduction of the number and complexity of study visits, study procedures and questionnaire 
burden are important but likely only partial solutions to increased trials participation. In this regard, 
the development of large simple trials (e.g. Heart Protection Study [24] and CRASH [25]) has been 
important. The Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction (TASTE) trial 
[26], a trial of thrombus aspiration before PCI versus usual best care prior to PCI involved 7244 
participants and had a primary endpoint of 30-day all-cause mortality. The trial used a national 
registry (Swedish Coronary Angiography and Angioplasty Registry (SCAAR)), achieving high 
participation due to simple design and no need for additional study follow-up. The trial did not show 
a differential response to the treatments. 
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Informed consent is a barrier to unselected participant recruitment. To guarantee everyone eligible 
is included, this requirement would need to be waived. In some contexts it is possible, subject to 
ethical approval, to conduct trials without or with modified consent. The  Post-Myocardial Infarction 
Free Rx Event and Economic Evaluation (MI FREEE) cluster based trial [27] of usual versus full 
prescription coverage randomized 2980 healthcare plan sponsors, with a primary endpoint of first 
major vascular event or revascularization. In this study, which required consent from plan sponsors 
but not from patients, the elimination of copayments for drugs prescribed after myocardial 
infarction did not significantly reduce rate of the trial’s primary outcome. A trial of emergency short 
term use of antiseptic versus antibiotic-coated versus plain latex catheters, to investigate the impact 
on the primary outcome of the incidence of symptomatic urinary tract infection for which an 
antibiotic was prescribed within 6 weeks, was analyzed in 6394 participants. [28] It randomized 
participants with retrospective consent after the initial admission. Routine use of antimicrobial-
impregnated or antiseptic-coated catheters was not supported by the results of this trial. 
 
If a trial neither interferes with normal clinical care nor adds non-standard activities or data 
collection, the objection to waiving consent is reduced. In low risk contexts, randomization of 
patients to alternative established treatments may be possible without consent [19], as might a 
cluster design to randomize physicians to prescribe only one of the alternative treatments. CRASH 
randomised >10,000 patients with head injury and impaired consciousness to determine if 
glucocorticoids, compared to placebo, impacted death and neurological disability.  It was stopped 
early due to evidence that glucocorticoid treatment increased mortality [25]. In CRASH the nature of 
consent depended on local ethics decisions, with the need for consent being waived in many cases. 
 
Cluster randomization as in MI FREE [27], involving groups of individuals (in the same healthcare 
facility) randomized to the same intervention, is popular in pragmatic trials. Cluster-cluster trials 
randomize clusters with outcomes aggregated at the cluster level, while cluster-individual trials have 
individual level outcomes. Cluster-cluster trials offer greater possibilities of waiver of cluster 
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member level consent [21, 29]. Cluster-individual trials offer the option of waiver of consent for the 
intervention with consent for participant follow-up. This approach was implemented in ASSIST, a 
cluster-randomized trial of a high school smoking prevention intervention with a primary outcome of 
smoking in the past week [30].  The trial suggested that the ASSIST intervention could lead to a 
reduction in adolescent smoking prevalence of public-health importance. 
 
The ongoing High-STEACS trial [31] is investigating the clinical implications of a high sensitivity 
troponin-I biomarker for diagnosis of myocardial infarction with a primary outcome of cardiovascular 
death or recurrent myocardial infarction within 12 months of admission. Like MI FREE, this is a trial 
of policy change.  It uses a stepped-wedge cluster design [32] where all sites transition from control 
to active intervention, but with randomization allocating the timing of transition with some sites 
allocating patients before others.  Such trials of a policy which is going to be implemented anyway 
arguably offer the greatest potential for pragmatic studies with no individual consent while allowing 
for some degree of control of ecological changes in care that may be happening simultaneously. 
 
To summarize, pragmatic trials face some unique and many of the same challenges that are seen 
with traditional explanatory trials. Strategies to enhance recruitment have been proposed [33]. 
Where appropriate, various forms of cluster randomization offer advantages and may help avoid 
informed consent. Disease registries provide patient cohorts consented for registry inclusion, 
facilitating recruitment and follow-up. A related approach is the cohort multiple randomized design 
[34], within which a cohort of participants is recruited and consented for follow-up and possible 
recruitment into trials of new treatments versus standard care. In any particular trial, only 
participants randomized to the novel intervention are further consented, reducing the concerns of 
participants randomized to usual care.  
 
Recruitment of investigators (Dimension 3: Table 1) 
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Trials need investigators to take responsibility for recruitment, treatment and follow-up. Many 
health care professionals outside academic centers do not participate in clinical trials, in part 
because of the time pressures associated with delivery of their clinical duties and for some because 
they do not consider research to be a key component of their job. Hence, study investigators will 
often not provide the heterogeneity of practice present in usual care. In contrast, in the TASTE trial 
[26], investigators across Sweden contributing to a national quality registry were included. Good 
studies include a variety of investigators with a representative mix of experience appropriate to the 
intervention studied. The trial of short term use of antiseptic versus antibiotic-coated versus plain 
latex catheters [28] made significant efforts to include a heterogeneous group of hospitals, 
specialists and surgical procedures. Despite these examples, this is a dimension where many studies 
fail the pragmatism test. A pragmatic approach is easier where an intervention is implemented at a 
group rather than an individual level, one reason why pragmatic trials are commonly cluster 
randomized. In the ASSIST trial only 113 (48%) of 233 possible schools expressed an interest to 
participate in the study [26]. The percentage of potential clusters agreeing to take part will vary 
depending on the trial context. A trial run by an overarching authority may achieve much higher 
participation. For example, a hospital could insist on full involvement of all wards in a trial of 
approaches to infection control.  
 
The wrong type of heterogeneity can be harmful. For example, a study of community heart failure 
nurses in reducing emergency heart failure admissions, incorporating many countries with poorly 
developed health care systems, would not inform implementation in a developed healthcare system. 
Likewise if an intervention involves significant technical expertise, then that intervention should be 
delivered by individuals with an adequate throughput of patients to enable them to maintain their 
levels of expertise. This is particularly true in surgical trials where complex surgery is increasingly 
delivered in high throughput centers. This creates a conflict in designing pragmatic trials. Should we 
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conduct a study in the healthcare environment that currently exists, or in a context representing the 
current direction of travel in the relevant specialist area? 
 
If heterogeneity of response to the intervention is likely, a study must be large enough to permit an 
understanding of that heterogeneity; this may require a substantial increase in sample size to detect 
a treatment by sub-group interaction. Often, there will be power to detect treatment by sub-group 
interactions only in large individual patient level meta-analyses.  
 
Establishing a critical mass for the efficient trial conduct is crucial. Incentivizing investigators is 
important in the face of increasing demand to deliver clinical services more efficiently since research 
takes time over standard clinical care. The development of clinical networks and establishment of 
disease specific research communities is one way forward. Another would be to give credit to health 
professionals for research as a key component of professional work plans. In the United Kingdom 
these approaches along with the creation of a national network of registered as fit-for-purpose 
Clinical Trials Units has improved the recruitment and retention of clinical investigators and 
methodologists working together to deliver trials, avoiding the common approach of setting up a 
network to deliver a single trial that is then not reused for future studies [35].  
 
The intervention and its delivery within the trial (Dimensions 4,5 and 6: Table 1) 
A trial with blinded interventions is not fully pragmatic. In pragmatic trials the randomized group is 
commonly not masked. Efforts made to minimize biases in open trials include focusing outcomes on 
major events such as mortality and emergency hospital admissions as in Prospective Randomised 
Open Blinded Endpoint (PROBE) trials [36] such as the ASCOT-BPLA [37] and SPRINT [38] trials of the 
impact on cardiovascular events of different strategies for lowering blood pressure. However, the 
reporting of non-serious adverse events, reasons for treatment discontinuation and many patient 
reported outcomes, are subject to greater degrees of bias in open studies, impacting study quality. 
In the Initial Antidepressant Choice in Primary Care trial [39] of fluoxetine versus tricyclic drugs, a 
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policy trial of newer vs. older drugs as first line therapy for depression to study the consequences of 
initial antidepressant choice under usual care conditions, adverse events were a main study 
outcome. The open nature of the study could have compromised the integrity of this endpoint. In 
the trial, clinical and quality-of-life outcomes, and overall treatment costs provided no clear 
guidance on initial selection of fluoxetine or tricyclic drugs. The CRASH trial involved placebo control 
and blinding. Nonetheless, it had many pragmatic elements. In many situations the need to avoid 
reporting bias will override purist pragmatic considerations making blinding the optimal approach. In 
complex intervention trials where blinding the intervention is often impossible it is usually possible 
to blind the assessment of outcomes [36].  In any trial the advantages and disadvantages of blinding 
must be considered; blinding being particularly important where reporting of key endpoints or 
safety events could be biased in an open study. 
 
In pragmatic designs the intervention should be delivered as in normal practice, by staff with typical 
experience using routinely available equipment. The MI FREE trial [27] tested a treatment policy 
assessing drugs within a class with flexible doses (a pragmatic trial often investigates a technology, 
not specific approaches within that technology). The degree of support for participants in treatment 
persistence can influence outcome. Traditional trials have study visits involving discussion of 
compliance and recording of safety laboratory tests and other investigations beyond normal 
practice. A trial dominated by poor delivery of the protocol or intervention is of limited use. Ideally a 
balance should be achieved, taking into consideration both the intervention and its mode of 
delivery. Investigators should be given basic advice on how to achieve good outcomes for 
participants, and reasonable levels of training in novel interventions within the constraints of the 
environment within which the trial is conducted.  
 
The nature of study follow-up (Dimension 7 Table 1) 
Collecting trial outcomes unobtrusively is attractive, reducing participant and investigator burden 
without introducing artificial aspects to follow-up. This is most feasible in healthcare systems with 
9 
 
reliable and accessible electronic health records capturing the events of interest. This might be 
achievable where there is a unified electronic healthcare record, but is at present challenging in 
many countries. The High-STEACS trial [31] illustrates the potential of this approach, with no study-
specific data collection visits at all. Likewise, MI FREE [27] followed participants via a healthcare 
database with outcomes determined algorithmically. Record linkage to routinely collected health 
records in the West of Scotland Coronary Prevention Study (WOSCOPS) [40-43] illustrates the 
benefits in identifying serious adverse events and potentially replacing traditional within-trial 
endpoint determination, and in evaluating long-term post-study safety, efficacy and cost 
effectiveness.  An attractive alternative to electronic health record trials are trials of alternative 
interventions in patients already enrolled in disease or intervention specific registries that 
incorporate a detailed patient phenotype and long-term follow-up. This provides an efficient and 
low-cost opportunity for the conduct of pragmatic studies (e.g. TASTE [26]). 
 
The nature of study outcomes, their determination and analysis (Dimensions 8, 9 Table 1) 
Pragmatic endpoints should be important to patients, for example major life events (e.g. death, or 
emergency hospital admissions). Pragmatic trials are also often large, identifying modest treatment 
effects and assessing safety in unselected populations for under-investigated interventions. They are 
also often simple, minimizing study procedures and data collection requirements. The CRASH trial 
[29] achieved a high degree of simplicity with a 2-page case report form. The catheter study [28] had 
a primary outcome of symptomatic catheter associated UTI up to 6 weeks post hospital discharge, 
rather than lab-confirmed infections in hospital, emphasizing the importance of health resource 
usage over mechanistic outcomes.    
 
Symptoms, disability and quality of life are commonly key outcomes in pragmatic trials. Unlike major 
life events, signs and symptoms and quality of life measures are seldom recorded consistently in 
routine practice requiring patient visits or completion of questionnaires. Pragmatic trials often use 
mailed questionnaires or web-based forms to avoid study visits. This reduces cost but can incur 
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substantial missing data with challenges for analysis and interpretation. Offering participants 
alternative methods of providing responses, including mobile phones and other handheld devices 
might increase response rates. Research into shorter effective Patient Reported Outcome 
questionnaires continues [43]. The ASSIST trial [26] achieved a > 90% return of self-reported data, an 
unusually high level. In mental health and other areas where many outcomes are questionnaire 
based, direct follow-up is difficult to avoid.  For example, the Initial Antidepressant Choice in Primary 
Care trial, [37] (a study with an otherwise pragmatic design), had study visits at 1, 3, 6, 9, 12, 18, and 
24 months after randomization. The main results of the trial were based on the first three study 
visits and 91% of these visits were completed. Quality of life outcomes play an important role in 
cost-effectiveness analyses, a common feature of pragmatic trials as illustrated in MI FREE [27] and 
the Initial Antidepressant Choice in Primary Care trial of fluoxetine versus tricyclic drugs study [37].  
Clearly, quality of life outcomes cannot be collected in a no-consent study such as MI FREE or in 
studies with follow-up within a registry or electronic health system such as High-STEACS [31] and 
TASTE [26], unless routinely recorded.  
 
Pragmatic trials can provide long-term safety data in unselected populations. However, there are 
challenges in interpreting safety data which is often self-reported, or is subject to delays in 
availability, incompleteness, and coding variability associated with national registries. Explanatory 
trials can also present adverse event related interpretational challenges, as events are sometimes 
not collected after withdrawal from randomized treatment, introducing bias into statistical analyses. 
 
It has been argued that pragmatic outcomes should not need adjudication. We believe this is a 
quality, rather than a pragmatic issue. If the quality and consistency of outcome ascertainment can 
be improved by adjudication without impacting normal patient care then surely that is desirable. 
 
Discussion 
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Drug development involves cautious introduction of a novel substance into human subjects with 
gradual evaluation in patients with the relevant disease, to evaluate safety, early evidence of 
efficacy and appropriate doses for future evaluation. The development of non-drug interventions 
should, but often do not, involve proof of concept or pilot studies to tailor the intervention and 
evaluate its acceptability. Many such interventions also require selection of a dose, such as duration 
and intensity of physiotherapy or physical training. These trials by their nature could be, but need 
not be, pragmatic as they involve careful refinement of the intervention and assessment of potential 
value in clinical practice.  
 
It is only after Phase III drug trials that we have any real understanding of whether the treatment is 
beneficial, who might benefit most, potential adverse effects and where the technology might be 
most cost-effectively implemented. The ideal time to carry out a pragmatic trial would be in the 
implementation stage of a complex intervention or the post-marketing phase of a drug, to help us 
understand what the impact of introducing the new technology might be on overall public health. 
This raises the question of who should pay for these studies. For drugs and devices, industry might 
feel that they have already done their bit getting a drug to the registration stage. Perhaps the best 
solution would be joint industry/ governmental funding.  
 
Some studies by their context, and the intervention studied, are more pragmatic than others. 
Studies where the intervention is low cost, with few risks to participants and/or is applied at a 
cluster level, will almost automatically be more pragmatic in nature or easier to organize in a 
pragmatic fashion than studies with high cost complex interventions. Healthcare systems with 
comprehensive electronic records or with condition-specific registries offer excellent environments 
for pragmatic low-cost studies. 
 
The conflict between mechanistic and pragmatic trials is often expressed as ‘greater internal validity 
of mechanistic studies’ compared with ‘improved external validity of pragmatic trials’. Price et al [45] 
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describe two pragmatic trials to evaluate the real-world effectiveness of a leukotriene-receptor 
antagonist (LTRA) compared with either an inhaled glucocorticoid for first-line asthma-controller 
therapy or a long-acting beta2-agonist (LABA) as add-on therapy in patients already receiving inhaled 
glucocorticoid therapy. Study results at two months suggested that LTRA was equivalent to an 
inhaled glucocorticoid as first-line controller therapy and to LABA as add-on therapy for diverse 
primary care patients. Equivalence was not established at two years. Non-adherence to the 
prescribed regimen was a major limitation. To mimic real-world practice, the investigators 
constructed two treatment strategies that rapidly developed considerable similarity. This undercut 
study power to detect differences in effectiveness of the drugs under investigation. They noted that 
‘the very features of pragmatic trials that support the generalizability, or applicability, of their results 
to real-world practice may also reduce assay sensitivity and therefore limit the interpretation of 
results’. These features include heterogeneous patient populations some of whom may not have the 
condition of interest, a lack of blinding, absence of a placebo group, and sub- optimal therapy 
adherence.   
 
The integration of research and clinical practice by the development of ‘‘learning healthcare 
systems’’ advocated by the Institute of Medicine [46], with relevant clinical and patient reported 
outcome data collected by default, would create a natural environment for clinical research, 
although some have questioned whether this is feasible given the clinical delivery pressures within 
today’s healthcare systems. [47, 48] 
 
Pragmatism should not be synonymous with a laissez faire approach to trial conduct. The aim is to 
inform clinical practice and that can only be achieved by high quality trials. We believe that the 
concepts of internal and external validity and even the dichotomy between explanatory and 
pragmatic trials are overly simplistic. A better approach is to assess how a trial design adequately 
addresses the study’s main objectives including its ability to inform clinical practice. 
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Conclusion 
Some trials need not be forced to be pragmatic and others will naturally have pragmatic features 
because of the nature of the intervention and the healthcare context they are conducted in. Very 
few trials can be fully pragmatic. Studies of truly novel interventions can be game changers without 
being particularly pragmatic. No single trial, pragmatic or otherwise, is likely to answer all potential 
questions about the value of any healthcare technology. A pragmatic approach to pragmatism would 
be to adopt pragmatic trial features wherever feasible and sensible and where this does not 
compromise study quality and the ability to answer the clinical question of interest. 
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Table 1: The nine dimensions for assessing the level of pragmatism in a trial, as proposed inPRECIS-2 
[grouped into four higher level domains]. 
Recruitment of investigators and participants 
1. Eligibility—To what extent are the participants in the trial similar to those who would receive this 
intervention if it was part of usual care? 
2. Recruitment—How much extra effort is made to recruit participants over and above what would 
be used in the usual care setting to engage with patients? 
3. Setting—How different are the settings of the trial from the usual care setting? 
The intervention and its delivery within the trial 
4. Organisation—How different are the resources, provider expertise, and the organisation of care 
delivery in the intervention arm of the trial from those available in usual care? 
5. Flexibility (delivery)—How different is the flexibility in how the intervention is delivered and the 
flexibility anticipated in usual care? 
6. Flexibility (adherence)—How different is the flexibility in how participants are monitored and 
encouraged to adhere to the intervention from the flexibility anticipated in usual care? 
The nature of study follow-up 
7. Follow-up—How different is the intensity of measurement and follow-up of participants in the 
trial from the typical follow-up in usual care? 
The nature of study outcomes their determination and analysis 
8. Primary outcome—To what extent is the trial’s primary outcome directly relevant to participants? 
9. Primary analysis—To what extent are all data included in the analysis of the primary outcome? 
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Table 2: Exemplar trials and their main pragmatic features – highlighting the important design features that make these trials pragmatic  
 
Trial Recruitment of investigators and 
participants 
The intervention and its 
delivery 
Study follow-up study outcomes, their 
determination and analysis 
Thrombus Aspiration 
during ST-Segment 
Elevation 
Myocardial Infarction  
(TASTE) 
Registry Based RCT. Participants 
randomised within an existing registry for 
coronary angiography and angioplasty.  
The intervention was 
thrombus aspiration before  
No study follow-up visits. Study data and outcomes extracted 
from registry database and record 
linkage to a national discharge 
registry.  
No study specific 
validation of national 
registry procedures or 
outcomes.  
PCI or usual best care prior 
to PCI. High level of participation (~60% of 
eligible participants). Individual consent 
for the trial. Initial oral consent confirmed 
in writing within 24 hours. 
Safety – meta-analysis suggested 
increased risk of stroke.  Sample size increased due 
to low event rate. No loss to follow up.  
Post-Myocardial 
Infarction Free Rx 
Event and Economic 
Evaluation  
(MI FREEE) 
Cluster design, no individual participant 
consent.  
Insurance plan sponsors 
randomised to usual or full 
prescription coverage. 
Participants followed up 
remotely.  
Study outcomes determined 
algorithmically from healthcare 
databases. Controlled policy study (“value-based 
insurance design” or “evidence- based 
plan design”). 
Study follow up changed 
from a minimum of 1 year 
to minimum of 3 months.  
No special clinical 
interventions, all drugs 
within a class considered  
Economic evaluation.  
No patient reported outcomes 
(consistent with no consent) or 
safety reporting (increased 
compliance could mean higher side 
effects). 
Excluded those whose medications 
already fully covered. Study administered by 
commercial insurer.  
Antimicrobial catheters 
for reduction of 
symptomatic 
urinary tract infection 
(UTI) in adults 
requiring short-term 
catheterisation in 
hospital  
Individually randomized trial of 3 catheter 
types in elective and emergency contexts.  
Open  design, active control,  
Impractical to blind 
catheters. 
Primary outcome 
symptomatic catheter 
associated UTI. Secondary 
outcome confirmed 
catheter-associated UTI.  
Hospital and community 
based follow up (6 weeks 
post catheter removal). 
No differences found, in contrast to 
the meta-analysis of generally 
small, single centre explanatory 
RCT – publication bias, highly select 
populations, lab-based outcomes.  
Retrospective consent for emergency 
cases.  50% of emergencies did not 
confirm consent. Heterogeneity of hospitals, specialties and 
surgical procedures. 
 
4% did not get a catheter, 
and another 4% did not get 
the catheter they were 
allocated to.  
Intravenous 
corticosteroid in adults 
with head injury  
(CRASH) 
Individually randomised, placebo 
controlled 
 
 
 
No consent (emergency 
surgery) – with local 
variations. 
Very simple: pragmatic 
outcome – all cause 
mortality; two page case 
report form; no record of 
concomitant medications 
or procedures. 
Randomised around 10,000 in 239 
hospitals in 49 countries. Follow up 
>99%, adherence 98%, 99% 
received the full dose. Study 
terminated early due to excess 
deaths on steroids.  
Fixed dose of steroid to 
simplify, any patient eligible 
if treating doctor uncertain 
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about giving steroids. Immediate impact on practice. 
An informal school-
based peer-led 
intervention for 
smoking prevention in 
adolescence 
 (ASSIST) 
Cluster public health RCT of  59 schools 
(10730 pupils) 
Complex intervention – 
smoking advice delivered by 
consensus identified class 
‘leaders’. 
Saliva samples for cotinine 
measurement 
Analysis complicated – ‘three tier 
hierarchical repeated measures 
model’ 127/233 schools expressed an interest. 66 
randomly selected from 113 agreeing.  
Individual consent for follow-up in a 
vulnerable group. 
High response rates (>90%). Low 
proportion withdrawn by parents 
(at start) or refused to participate 
(<5%).  
Randomised at school level, 
outcomes aggregated at 
school level (year group). 
High-Sensitivity 
Troponin in the 
Evaluation of Patients 
With Acute Coronary 
Syndrome  
(High-STEACS) 
Stepped Wedge diagnostic policy study.  
Hospitals randomised to use standard 
Tropinin I assay or high sensitive Troponin 
I assay for the diagnosis of myocardial 
infarction.  
The new assay introduced 
into normal care pathways. 
Hospitals used older assay 
for all chest pain admissions 
until their randomised 
switch time after which the 
new assay was used for all 
chest pain admissions. 
No study specific visits. 
Main outcome 1 year 
cardiovascular death or 
recurrent myocardial 
infarction. 
Study outcomes determined by 
linkage to national electronic 
databases of hospital discharge 
summaries, deaths, and other 
medical records.  
No individual consent for trial. Consent required for 
samples for explanatory 
lab-based sub-study. 
Outcome to be analysed using a 
‘Safe Harbour’ approach. 
Effectiveness and Cost 
of Fluoxetine 
vs Tricyclic 
Antidepressants 
(Initial Antidepressant 
Choice in Primary Care) 
Head-to-head ‘policy’ RCT of newer vs. 
older drugs as first line therapy for 
depression to study the consequences of 
initial antidepressant choice under usual 
care conditions. 
Open study to preserve 
usual care approach. 
Comorbidity or severity of 
depression not exclusions.  
6% ineligible, 7% refused. 
No restriction on doses of 
study or concomitant drugs. 
Follow-up assessments at 
1, 3, 6, 9, 12, 18, and 24 
months after 
randomization. 
Interviewers blinded to 
study intervention. 
Multiple outcomes: clinical and 
cost effectiveness; adverse effects; 
quality of life. No restrictions on 
crossovers /discontinuations. May 
not be generalizable to different 
healthcare systems.  
Leukotriene 
Antagonists as First-
Line or Add-on 
Asthma-Controller 
Therapy 
Primary care, head-to-head RCT 
Equivalence design 
Open label pragmatic trial 
comparing technologies, 
choice of drug within a class 
left to local preference. 
Around 6% post-
randomization exclusions, 
perhaps unusual in a 
pragmatic trial. 
Identified features: Intention to treat analysis with per-
protocol as back up. Multiple 
imputation used for missing data. 
Study lacked power due to more 
variability in outcome than 
expected (more heterogeneous 
population, lower compliance, 
crossovers). 
 Patient heterogeneity 
 Blinding 
 No placebo (assay 
sensitivity?) 
 Poor compliance  
 Treatment crossovers 
 
 
